Candida News and Research

RSS

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Enzymerx completes enrollment for clinical trial of pegsitacase

EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

22 Feb 2010

New Candida treatment more effective than popular remedies

Kathleen Kalaf has been to hell and back in her long fight with systemic Candida. Today, thanks to a new Candida treatment that is more effective than even the most popular Candida remedies, Kalaf is finally free of the yeast overgrowth that stole eight years of her life -- and she wants other Candida sufferers to know about Candida Force (http://www.candidaforce.com).

28 Jan 2010

Rituximab treatment reduces patients' response to pneumonia vaccine

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA).

7 Jan 2010

Safe living guidelines for transplant recipients

Keeping pets healthy can reduce infection risks for people who have received solid organ transplants and veterinarians should be seen as an integral part of the healthcare team. That's just one of the key pieces of advice from a safe living article published in an infectious diseases supplement in the American Journal of Transplantation.

18 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

Pilot clinical study results of laser treatment for toenail fungus presented

PinPointe USA, Inc., a privately held emerging medical technology company which introduced the breakthrough PinPointe FootLaser treatment for toenail fungus in Europe, today announced that Dr. Brian McDowell presented the results of his pilot clinical study “Laser Treatment for Toenail Fungus” (Harris, McDowell and Strisower, Proc. SPIE 7161A, 2009) at the Society of Chiropodists and Podiatrists Annual Conference 2009 at Harrogate International Centre on November 19.

25 Nov 2009

American Biotech Labs' ASAP Antibacterial Silver Gel receives FDA 510(k) medical device clearance

American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has obtained clearance by the U.S. Food and Drug Administration (FDA) to market its ASAP Antibacterial Silver Wound Dressing Gel as a prescription 510(k) medical device throughout the United States. Clifton Mining Company is a major shareholder in American Biotech Labs.

17 Nov 2009

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.

2 Nov 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.

29 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

Preachers Coffee signs agreement to enhance its nutraceutical-health marketing strategy

PREACHERS COFFEE, INC. (PINKSHEETS: PRCF) in order to enhance its Nutraceutical Health Marketing Strategy entered into an Agreement with "GANO EXCEL COFFEE COMPANY" -- a robust Multi Level Marketing Health Coffee Company that has a broad range of 3,000,000 customers with respect to population and followings.

23 Oct 2009

61 institutions awarded grants for cancer research from American Cancer Society

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010.

3 Oct 2009

Investigational New Drug application for Uricase-PEG 20 approved

EnzymeRx, LLC, a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective.

25 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009